Shuang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuang Li has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Dawei Zou
Immunobiology & Transplant Science Center, Department of Surgery, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, USA
4 shared publications - Anahita Mojiri
Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, TX (S.L., R.K.R., A.J.L., F.N., M.G., K.N.C., L.L., A.M., K.A.Y., J.P.C.).
3 shared publications - John P. Cooke
Department of Cardiovascular Sciences, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX 77030, USA
3 shared publications - Alexander J. Lu
Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, TX (S.L., R.K.R., A.J.L., F.N., M.G., K.N.C., L.L., A.M., K.A.Y., J.P.C.).
2 shared publications - Arvind Bhimaraj
Department of Cardiology, DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX, United States
2 shared publications - Chang Liu
Department of Endoscopy Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Springer Nature in Nature Communications
A stem-like CD8+ T cell reservoir resists exhaustion and sustains alloimmunity a decade after transplantation
Chronic antigen exposure is commonly thought to drive CD8 + T cells toward exhaustion. However, in transplantation, we show that sustained immunity is maintained by a persistent stem-like reservoir that iteratively replenishes short-lived cytotoxic effectors rather than progressing toward exhaustion. Analysis of rejected human kidney allografts obtained approximately 10 years after transplantation reveals extensive overlap of CD8 + T-cell clonotypes between the circulation and allografts. These clones are maintained in a TCF1 + stem-like state in the circulation but differentiate into TCF1 − cytotoxic effectors within allografts. Mouse models demonstrate that cytotoxic effector differentiation is restrained by TCF1 and depends on lactate dehydrogenase A. Cytotoxic effectors are short-lived and insufficient to mediate allograft rejection upon transfer into secondary hosts, whereas stem-like T cells retain self-renewal capacity, continuously replenish cytotoxic effectors, and drive rejection across serial transplantations. These findings establish a principle whereby a stem-like CD8 + T-cell reservoir drives sustained alloimmunity through continuous effector differentiation.
- 31 October 2026
- Published by Springer Nature in Nature Communications
Open AccessA stem-like CD8+ T cell reservoir resists exhaustion and sustains alloimmunity a decade after transplantation
Chronic antigen exposure is commonly thought to drive CD8 + T cells toward exhaustion. However, in transplantation, we show that sustained immunity is maintained by a persistent stem-like reservoir that iteratively replenishes short-lived cytotoxic effectors rather than progressing toward exhaustion. Analysis of rejected human kidney allografts obtained approximately 10 years after transplantation reveals extensive overlap of CD8 + T-cell clonotypes between the circulation and allografts. These clones are maintained in a TCF1 + stem-like state in the circulation but differentiate into TCF1 − cytotoxic effectors within allografts. Mouse models demonstrate that cytotoxic effector differentiation is restrained by TCF1 and depends on lactate dehydrogenase A. Cytotoxic effectors are short-lived and insufficient to mediate allograft rejection upon transfer into secondary hosts, whereas stem-like T cells retain self-renewal capacity, continuously replenish cytotoxic effectors, and drive rejection across serial transplantations. These findings establish a principle whereby a stem-like CD8 + T-cell reservoir drives sustained alloimmunity through continuous effector differentiation.
- 26 May 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (21) , 1661-1678
Recovery From Heart Failure: Microvascular Mechanisms
BACKGROUND: Heart failure (HF) is a significant global health problem. Left ventricular assist device (LVAD) implantation serves as a bridge for patients awaiting heart transplantation. Intriguingly, LVAD support often improves cardiac histology and function, sometimes enough to avoid transplantation after LVAD removal. However, the cellular programs underlying this recovery remain unclear. METHODS: Myocardial tissues were obtained from patients with HF at the time of LVAD implantation (pre LVAD) and explantation (post LVAD) for histological analysis and single-nucleus RNA sequencing. A murine model of HF recovery, combined with lineage tracing studies, was employed to define cellular sources of vascular repair. Cardiac function, fibrosis, and vascular density were assessed using echocardiography, histology, and fluorescent microsphere perfusion. A patient-derived cardiac nonmyocyte culture system was established to interrogate mechanisms of cell fate regulation. RESULTS: Post-LVAD myocardial tissues exhibited reduced fibrosis and increased capillary density compared with pre-LVAD samples. Across samples, fibroblast abundance was inversely correlated with endothelial cell abundance, consistent with enhanced angiogenesis during recovery. Single-nucleus RNA sequencing identified a fibroblast subset predisposed to undergo mesenchymal-to-endothelial transition, acquiring an endothelial cell identity. Additionally, nonmyocytes from pre-LVAD hearts proliferated poorly and failed to form vascular structures, whereas nonmyocytes from post-LVAD hearts displayed greater proliferation and angiogenesis capacity, forming vessel-like structures, reinforcing the association of HF recovery with angiogenic reprogramming. Mechanistically, knockdown of c-Myc (cellular myelocytomatosis oncogene) by small interfering RNA shifted post-LVAD nonmyocytes to a pre-LVAD–like state, while c-Myc overexpression by mRNA in pre-LVAD cells induced a post-LVAD–like phenotype, implicating c-Myc as 1 contributor to this fate switch. A model of HF recovery in mice mimicked the histological and functional changes in patients, with physiological evidence of increased microvascular perfusion, associated with a fibroblast-to-endothelial transition, documented by lineage tracing. CONCLUSIONS: HF recovery involves reduced fibrosis and enhanced microvascularization, partly driven by fibroblast-to-endothelial cell fate transition. c-Myc functions as 1 regulator of this transition, offering a mechanistic entry point to develop regenerative therapies in HF.
- 26 May 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (21) , 1661-1678
Recovery From Heart Failure: Microvascular Mechanisms
BACKGROUND: Heart failure (HF) is a significant global health problem. Left ventricular assist device (LVAD) implantation serves as a bridge for patients awaiting heart transplantation. Intriguingly, LVAD support often improves cardiac histology and function, sometimes enough to avoid transplantation after LVAD removal. However, the cellular programs underlying this recovery remain unclear. METHODS: Myocardial tissues were obtained from patients with HF at the time of LVAD implantation (pre LVAD) and explantation (post LVAD) for histological analysis and single-nucleus RNA sequencing. A murine model of HF recovery, combined with lineage tracing studies, was employed to define cellular sources of vascular repair. Cardiac function, fibrosis, and vascular density were assessed using echocardiography, histology, and fluorescent microsphere perfusion. A patient-derived cardiac nonmyocyte culture system was established to interrogate mechanisms of cell fate regulation. RESULTS: Post-LVAD myocardial tissues exhibited reduced fibrosis and increased capillary density compared with pre-LVAD samples. Across samples, fibroblast abundance was inversely correlated with endothelial cell abundance, consistent with enhanced angiogenesis during recovery. Single-nucleus RNA sequencing identified a fibroblast subset predisposed to undergo mesenchymal-to-endothelial transition, acquiring an endothelial cell identity. Additionally, nonmyocytes from pre-LVAD hearts proliferated poorly and failed to form vascular structures, whereas nonmyocytes from post-LVAD hearts displayed greater proliferation and angiogenesis capacity, forming vessel-like structures, reinforcing the association of HF recovery with angiogenic reprogramming. Mechanistically, knockdown of c-Myc (cellular myelocytomatosis oncogene) by small interfering RNA shifted post-LVAD nonmyocytes to a pre-LVAD–like state, while c-Myc overexpression by mRNA in pre-LVAD cells induced a post-LVAD–like phenotype, implicating c-Myc as 1 contributor to this fate switch. A model of HF recovery in mice mimicked the histological and functional changes in patients, with physiological evidence of increased microvascular perfusion, associated with a fibroblast-to-endothelial transition, documented by lineage tracing. CONCLUSIONS: HF recovery involves reduced fibrosis and enhanced microvascularization, partly driven by fibroblast-to-endothelial cell fate transition. c-Myc functions as 1 regulator of this transition, offering a mechanistic entry point to develop regenerative therapies in HF.
- 24 May 2025
- Published by Elsevier in Toxicology
- Vol. 517, 154198
Perfluoroalkyl substance pollutants disrupt microglia function and trigger transcriptional and epigenomic changes
- 24 May 2025
- Published by Elsevier in Toxicology
- Vol. 517, 154198
Perfluoroalkyl substance pollutants disrupt microglia function and trigger transcriptional and epigenomic changes
- 28 March 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (7) , 1582-1583
Letter in reference to “Immunomodulation of T cell-mediated alloimmunity by proximity to endothelial cells under mTOR blockade”
- 28 March 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (7) , 1582-1583
Letter in reference to “Immunomodulation of T cell-mediated alloimmunity by proximity to endothelial cells under mTOR blockade”
- Open Access
Telomerase mRNA Reduces Radiation-induced DNA Damage of human skin
Over four million people undergo radiation therapy annually in the United States. Among these, more than 90% experience varying degrees of radiation-induced skin injury. Despite the enormity of the problem, there is currently no FDA-approved agent to prevent or treat skin damage caused by ionizing radiation. In the current study, ionizing radiation induced dose-dependent genomic and mitochondrial DNA damage, leading to apoptosis in primary cutaneous cells. Prior treatment with mRNA encoding telomerase reverse transcriptase (TERT) substantially reduced radiation-induced DNA damage in human primary skin cells and tissues. Mechanistically, TERT mRNA pretreatment enhances DNA repair, reduces mitochondrial ROS, and decreases apoptosis without extending telomere length during the experimental period, suggesting a non-canonical function of TERT to accelerate the cellular recovery from radiation. These findings highlight a potential therapeutic approach for preventing radiation-induced skin injury. Graphic
Open AccessTelomerase mRNA Reduces Radiation-induced DNA Damage of human skin
Over four million people undergo radiation therapy annually in the United States. Among these, more than 90% experience varying degrees of radiation-induced skin injury. Despite the enormity of the problem, there is currently no FDA-approved agent to prevent or treat skin damage caused by ionizing radiation. In the current study, ionizing radiation induced dose-dependent genomic and mitochondrial DNA damage, leading to apoptosis in primary cutaneous cells. Prior treatment with mRNA encoding telomerase reverse transcriptase (TERT) substantially reduced radiation-induced DNA damage in human primary skin cells and tissues. Mechanistically, TERT mRNA pretreatment enhances DNA repair, reduces mitochondrial ROS, and decreases apoptosis without extending telomere length during the experimental period, suggesting a non-canonical function of TERT to accelerate the cellular recovery from radiation. These findings highlight a potential therapeutic approach for preventing radiation-induced skin injury. Graphic
- Open Access
Recovery from Heart Failure is a Vascular Recovery
Heart failure (HF) remains a major cause of morbidity and mortality worldwide, with limited treatment options. Heart transplantation is an end stage option but limited by donor availability. Left-ventricular assist device (LVAD) implantation serves as a bridging strategy for patients awaiting a transplant. Intriguingly, LVAD support (typically for 6-12 months before heart transplantation) is often associated with some level of improvement in cardiac function and histology. In rare cases, LVAD support can improve cardiac function sufficiently to avoid heart transplantation after LVAD removal. The underlying mechanisms of this improvement in cardiac function are not understood. Here, we provide evidence that the improvement in cardiac function post-LVAD is associated with a reduction in fibrosis and an increase in capillary density. This heart failure recovery (HFR) is also associated with an angiogenic cell fate transition. We observed a distinct pro-angiogenic phenotype of cardiac non-myocytes isolated from post-LVAD hearts. Single-nuclei RNA sequencing of pre- and post-LVAD cardiac tissue reveals a fibroblast subtype that undergoes mesenchymal to endothelial transition (MEndoT), potentially facilitating HFR. In a murine model of HFR, lineage tracing studies confirm that MEndoT is associated with the increase in capillary density and perfusion during HFR. In summary, our results support the new concept that HFR is associated with a reduction in interstitial cardiac fibrosis, an increase in capillary density and perfusion, that is due in part to an angiogenic cell fate transition. Our work represents a shift in the conceptual framework regarding mechanisms of HFR, and a new therapeutic avenue for exploration.
Open AccessRecovery from Heart Failure is a Vascular Recovery
Heart failure (HF) remains a major cause of morbidity and mortality worldwide, with limited treatment options. Heart transplantation is an end stage option but limited by donor availability. Left-ventricular assist device (LVAD) implantation serves as a bridging strategy for patients awaiting a transplant. Intriguingly, LVAD support (typically for 6-12 months before heart transplantation) is often associated with some level of improvement in cardiac function and histology. In rare cases, LVAD support can improve cardiac function sufficiently to avoid heart transplantation after LVAD removal. The underlying mechanisms of this improvement in cardiac function are not understood. Here, we provide evidence that the improvement in cardiac function post-LVAD is associated with a reduction in fibrosis and an increase in capillary density. This heart failure recovery (HFR) is also associated with an angiogenic cell fate transition. We observed a distinct pro-angiogenic phenotype of cardiac non-myocytes isolated from post-LVAD hearts. Single-nuclei RNA sequencing of pre- and post-LVAD cardiac tissue reveals a fibroblast subtype that undergoes mesenchymal to endothelial transition (MEndoT), potentially facilitating HFR. In a murine model of HFR, lineage tracing studies confirm that MEndoT is associated with the increase in capillary density and perfusion during HFR. In summary, our results support the new concept that HFR is associated with a reduction in interstitial cardiac fibrosis, an increase in capillary density and perfusion, that is due in part to an angiogenic cell fate transition. Our work represents a shift in the conceptual framework regarding mechanisms of HFR, and a new therapeutic avenue for exploration.
- Open Access
- 6 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (6) , 1093-1094
“Please don’t lyse me”: Programmed cell death ligand-1 expression on neonatal islet cells promotes xenotransplant acceptance
- 6 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (6) , 1093-1094
Open Access“Please don’t lyse me”: Programmed cell death ligand-1 expression on neonatal islet cells promotes xenotransplant acceptance
- Open Access
- 6 November 2023
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 136 (22) , 2658-2667
Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure
Although antiretroviral therapy (ART) can reduce the viral load in the plasma to undetectable levels in human immunodeficiency virus (HIV)-infected individuals, ART alone cannot completely eliminate HIV due to its integration into the host cell genome to form viral reservoirs. To achieve a functional cure for HIV infection, numerous preclinical and clinical studies are underway to develop innovative immunotherapies to eliminate HIV reservoirs in the absence of ART. Early studies have tested adoptive T-cell therapies in HIV-infected individuals, but their effectiveness was limited. In recent years, with the technological progress and great success of chimeric antigen receptor (CAR) therapy in the treatment of hematological malignancies, CAR therapy has gradually shown its advantages in the field of HIV infection. Many studies have identified a variety of HIV-specific CAR structures and types of cytolytic effector cells. Therefore, CAR therapy may be beneficial for enhancing HIV immunity, achieving HIV control, and eliminating HIV reservoirs, gradually becoming a promising strategy for achieving a functional HIV cure. In this review, we provide an overview of the design of anti-HIV CAR proteins, the cell types of anti-HIV CAR (including CAR T cells, CAR natural killer cells, and CAR-encoding hematopoietic stem/progenitor cells), the clinical application of CAR therapy in HIV infection, and the prospects and challenges in anti-HIV CAR therapy for maintaining viral suppression and eliminating HIV reservoirs.
- 6 November 2023
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 136 (22) , 2658-2667
Open AccessTargeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure
Although antiretroviral therapy (ART) can reduce the viral load in the plasma to undetectable levels in human immunodeficiency virus (HIV)-infected individuals, ART alone cannot completely eliminate HIV due to its integration into the host cell genome to form viral reservoirs. To achieve a functional cure for HIV infection, numerous preclinical and clinical studies are underway to develop innovative immunotherapies to eliminate HIV reservoirs in the absence of ART. Early studies have tested adoptive T-cell therapies in HIV-infected individuals, but their effectiveness was limited. In recent years, with the technological progress and great success of chimeric antigen receptor (CAR) therapy in the treatment of hematological malignancies, CAR therapy has gradually shown its advantages in the field of HIV infection. Many studies have identified a variety of HIV-specific CAR structures and types of cytolytic effector cells. Therefore, CAR therapy may be beneficial for enhancing HIV immunity, achieving HIV control, and eliminating HIV reservoirs, gradually becoming a promising strategy for achieving a functional HIV cure. In this review, we provide an overview of the design of anti-HIV CAR proteins, the cell types of anti-HIV CAR (including CAR T cells, CAR natural killer cells, and CAR-encoding hematopoietic stem/progenitor cells), the clinical application of CAR therapy in HIV infection, and the prospects and challenges in anti-HIV CAR therapy for maintaining viral suppression and eliminating HIV reservoirs.
- Open Access
- 25 September 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (1) , 147-148
Harnessing mixed chimerism and programmed cell death protein 1/programmed death ligand 1 signaling for transplant tolerance
- 25 September 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (1) , 147-148
Open AccessHarnessing mixed chimerism and programmed cell death protein 1/programmed death ligand 1 signaling for transplant tolerance
- Open Access
- 21 September 2023
- Published by Springer Nature in Genome Medicine
- Vol. 15 (1) , 1-24
Long-read sequencing reveals the landscape of aberrant alternative splicing and novel therapeutic target in colorectal cancer
Background: Alternative splicing complexity plays a vital role in carcinogenesis and cancer progression. Improved understanding of novel splicing events and the underlying regulatory mechanisms may contribute new insights into developing new therapeutic strategies for colorectal cancer (CRC). Methods: Here, we combined long-read sequencing technology with short-read RNA-seq methods to investigate the transcriptome complexity in CRC. By using experiment assays, we explored the function of newly identified splicing isoform TIMP1 Δ4-5. Moreover, a CRISPR/dCasRx-based strategy to induce the TIMP1 exon 4–5 exclusion was introduced to inhibit neoplasm growth. Results: A total of 90,703 transcripts were identified, of which > 62% were novel compared with current transcriptome annotations. These novel transcripts were more likely to be sample specific, expressed at relatively lower levels with more exons, and oncogenes displayed a characteristic to generate more transcripts in CRC. Clinical outcome data analysis showed that 1472 differentially expressed alternative splicing events (DEAS) were tightly associated with CRC patients’ prognosis, and many novel isoforms were likely to be important determinants for patient survival. Among these, newly identified splicing isoform TIMP1 Δ4-5 was significantly downregulated in CRC. Further in vitro and in vivo assays demonstrated that ectopic expression of TIMP1 Δ4-5 significantly suppresses tumor cell growth and metastasis. Serine/arginine-rich splicing factor 1 (SRSF1) acts as a onco-splicing regulator through sustaining the inclusion of TIMP1 exon 4–5. Furthermore, CRISPR/dCasRx-based strategies designed to induce TIMP1 exon 4–5 exclusion have the potential to restrain the CRC growth. Conclusions: This data provides a rich resource for deeper studies of gastrointestinal malignancies. Newly identified splicing isoform TIMP1 Δ4-5 plays an important role in mediating CRC progression and may be a potential therapy target in CRC.
- 21 September 2023
- Published by Springer Nature in Genome Medicine
- Vol. 15 (1) , 1-24
Open AccessLong-read sequencing reveals the landscape of aberrant alternative splicing and novel therapeutic target in colorectal cancer
Background: Alternative splicing complexity plays a vital role in carcinogenesis and cancer progression. Improved understanding of novel splicing events and the underlying regulatory mechanisms may contribute new insights into developing new therapeutic strategies for colorectal cancer (CRC). Methods: Here, we combined long-read sequencing technology with short-read RNA-seq methods to investigate the transcriptome complexity in CRC. By using experiment assays, we explored the function of newly identified splicing isoform TIMP1 Δ4-5. Moreover, a CRISPR/dCasRx-based strategy to induce the TIMP1 exon 4–5 exclusion was introduced to inhibit neoplasm growth. Results: A total of 90,703 transcripts were identified, of which > 62% were novel compared with current transcriptome annotations. These novel transcripts were more likely to be sample specific, expressed at relatively lower levels with more exons, and oncogenes displayed a characteristic to generate more transcripts in CRC. Clinical outcome data analysis showed that 1472 differentially expressed alternative splicing events (DEAS) were tightly associated with CRC patients’ prognosis, and many novel isoforms were likely to be important determinants for patient survival. Among these, newly identified splicing isoform TIMP1 Δ4-5 was significantly downregulated in CRC. Further in vitro and in vivo assays demonstrated that ectopic expression of TIMP1 Δ4-5 significantly suppresses tumor cell growth and metastasis. Serine/arginine-rich splicing factor 1 (SRSF1) acts as a onco-splicing regulator through sustaining the inclusion of TIMP1 exon 4–5. Furthermore, CRISPR/dCasRx-based strategies designed to induce TIMP1 exon 4–5 exclusion have the potential to restrain the CRC growth. Conclusions: This data provides a rich resource for deeper studies of gastrointestinal malignancies. Newly identified splicing isoform TIMP1 Δ4-5 plays an important role in mediating CRC progression and may be a potential therapy target in CRC.